Thermo Fisher Scientific Inc. $TMO Stake Boosted by Voya Investment Management LLC

Thermo Fisher Scientific logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Voya Investment Management increased its Thermo Fisher stake by 200.3% in the third quarter, adding 516,007 shares to hold 773,639 shares valued at about $522 million.
  • Thermo Fisher reported quarterly earnings of $6.68 per share, beating estimates of $6.40; revenue rose 9.1% year over year to $12.14 billion, also above expectations.
  • Analysts’ consensus rating is “Moderate Buy”, with an average price target of $683.64. Institutional investors collectively own 89.23% of the stock.
  • Five stocks we like better than Thermo Fisher Scientific.

Voya Investment Management LLC lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 200.3% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 773,639 shares of the medical research company's stock after buying an additional 516,007 shares during the quarter. Voya Investment Management LLC owned approximately 0.21% of Thermo Fisher Scientific worth $522,246,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in TMO. BlackRock Inc. purchased a new position in Thermo Fisher Scientific in the second quarter worth approximately $15,501,867,000. Corient Private Wealth LP acquired a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $382,547,000. Bank of New York Mellon Corp purchased a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $1,974,561,000. Bank of America Corp DE acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at $1,952,930,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Thermo Fisher Scientific by 0.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,472,524 shares of the medical research company's stock valued at $1,239,625,000 after purchasing an additional 22,827 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on TMO shares. Weiss Ratings raised shares of Thermo Fisher Scientific from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Thursday, October 8th. Leerink Partners increased their target price on Thermo Fisher Scientific from $600.00 to $620.00 and gave the company an "outperform" rating in a report on Wednesday, July 22nd. UBS Group restated a "buy" rating and issued a $800.00 price target (up from $540.00) on shares of Thermo Fisher Scientific in a research note on Thursday, October 22nd. CLSA began coverage on Thermo Fisher Scientific in a report on Thursday, September 3rd. They set an "outperform" rating and a C$748.00 price target for the company. Finally, Wells Fargo & Company cut Thermo Fisher Scientific from an "overweight" rating to an "underweight" rating in a research report on Wednesday, September 9th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $683.64.

Read Our Latest Research Report on Thermo Fisher Scientific

Thermo Fisher Scientific Stock Down 0.7%

TMO stock opened at $686.70 on Wednesday. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.71. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $727.56. The company's 50 day moving average is $674.07 and its two-hundred day moving average is $557.70. The stock has a market cap of $254.43 billion, a P/E ratio of 36.22, a PEG ratio of 2.82 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, topping the consensus estimate of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The business had revenue of $12.14 billion during the quarter, compared to the consensus estimate of $11.95 billion. During the same quarter in the previous year, the firm earned $5.79 EPS. The company's revenue was up 9.1% compared to the same quarter last year. Research analysts expect that Thermo Fisher Scientific Inc. will post 25.26 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, January 15th. Investors of record on Tuesday, December 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, December 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.92%.

Insiders Place Their Bets

In related news, VP Lisa Britt sold 2,831 shares of the business's stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $706.45, for a total value of $1,999,959.95. Following the completion of the sale, the vice president directly owned 11,560 shares of the company's stock, valued at $8,166,562. The trade was a 19.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc Casper sold 275 shares of the company's stock in a transaction on Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the transaction, the chief executive officer owned 123,925 shares of the company's stock, valued at $77,707,171.25. This represents a 0.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 13,106 shares of company stock valued at $8,465,099. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.

Featured Articles

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Thermo Fisher Scientific Right Now?

Before you consider Thermo Fisher Scientific, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.

While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines